Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: A systematic review and meta-analysis.

The STEs for the HR of iPFS and cPFS were 0.75 and 1.21, respectively, which are the maximal HR for observed iPFS and cPFS needed to report possibly significant treatment effect on OS. 3.4 Trial‐level correlation between median OS and median iPFS/cPFS For the ICI arms evaluated by conventional criteria, the mean and standard deviation of median OS and median cPFS were 12.98 ± 5.33 months and 4.30 ± 2.39 months, respectively, whereas the mean and standard deviation of median OS and median iPFS were 10.14 ± 3.44 months and 4.93 ± 1.75 months for the ICI arms evaluated by immune‐related criteria.

also in 649 other papers